eMedI Chat 
Contact Us
eMedI Chat: Medical Information Database
eMedI Chat
eMedI Chat ONCOLOGY PIPELINE AGENTS
Please note that this page may contain information on EMD Serono, Inc. marketed and/or investigational products. Investigational agents and investigational indications for marketed products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee that any product will be approved in the sought-after indication. Please click here to view the full EMD Serono pipeline.
Immuno-oncology
Avelumab
Avelumab is an anti-PD-L1 antibody under clinical investigation in patients with solid tumors.
M6223
M6223 is an anti-TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) antibody under clinical investigation in patients with solid tumors.
Patient Resources
Research
Additional Oncology Resources
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 04/25
© 2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.